BACKGROUND: Pulmonary vein isolation (PVI) using the second-generation cryoballoon (CB2) in patients with paroxysmal and persistent atrial fibrillation (AF) has demonstrated encouraging acute and mid-term results. Follow-up data on outcome beyond 1-year is lacking. The purpose of this analysis was to investigate the 2-year clinical outcome after CB2-based PVI. METHODS: Sixty patients (age 62 ± 11 years) with paroxysmal [45/60 (75%) patients] or short-standing persistent AF [15/60 (25%) patients] underwent 28-mm CB2-based PVI. Freeze-cycle duration was 240 s. After successful PVI, a bonus freeze-cycle of the same duration was applied. Follow-up was based on outpatient clinic visits at 3, 6, 12, 18, and 24 months including 24 h Holter-ECGs and telephone interviews. Recurrence was defined as any symptomatic and/or documented atrial tachyarrhythmia (ATA) episode >30 s following a 3-month blanking period. RESULTS: A total of 231 pulmonary veins (PV) were identified and 230/231 (99.6%) PVs were successfully isolated. Phrenic nerve palsy occurred in 2/60 (3.3%) patients. No other periprocedural complications occurred. Follow-up was available for 59/60 (98%) patients with a mean duration of 838 ± 67 days. A total of 43/59 (73%) patients remained in stable sinus rhythm. In 10/16 (63%) patients with ATA recurrence, a repeat procedure was performed using radiofrequency energy. The overall success rate after a maximum of two ablation procedures and a follow-up period of 838 ± 67 days was 88% (52/59) patients. CONCLUSIONS: Patients with paroxysmal or short-persistent AF undergoing PVI using the 28-mm CB2 demonstrated a 73% 2-year single-procedure clinical success rate.
BACKGROUND: Pulmonary vein isolation (PVI) using the second-generation cryoballoon (CB2) in patients with paroxysmal and persistent atrial fibrillation (AF) has demonstrated encouraging acute and mid-term results. Follow-up data on outcome beyond 1-year is lacking. The purpose of this analysis was to investigate the 2-year clinical outcome after CB2-based PVI. METHODS: Sixty patients (age 62 ± 11 years) with paroxysmal [45/60 (75%) patients] or short-standing persistent AF [15/60 (25%) patients] underwent 28-mm CB2-based PVI. Freeze-cycle duration was 240 s. After successful PVI, a bonus freeze-cycle of the same duration was applied. Follow-up was based on outpatient clinic visits at 3, 6, 12, 18, and 24 months including 24 h Holter-ECGs and telephone interviews. Recurrence was defined as any symptomatic and/or documented atrial tachyarrhythmia (ATA) episode >30 s following a 3-month blanking period. RESULTS: A total of 231 pulmonary veins (PV) were identified and 230/231 (99.6%) PVs were successfully isolated. Phrenic nerve palsy occurred in 2/60 (3.3%) patients. No other periprocedural complications occurred. Follow-up was available for 59/60 (98%) patients with a mean duration of 838 ± 67 days. A total of 43/59 (73%) patients remained in stable sinus rhythm. In 10/16 (63%) patients with ATA recurrence, a repeat procedure was performed using radiofrequency energy. The overall success rate after a maximum of two ablation procedures and a follow-up period of 838 ± 67 days was 88% (52/59) patients. CONCLUSIONS:Patients with paroxysmal or short-persistent AF undergoing PVI using the 28-mm CB2 demonstrated a 73% 2-year single-procedure clinical success rate.
Authors: Alexander Fürnkranz; Stefano Bordignon; Daniela Dugo; Laura Perotta; Melanie Gunawardene; Britta Schulte-Hahn; Bernd Nowak; Boris Schmidt; Julian K R Chun Journal: J Cardiovasc Electrophysiol Date: 2014-05-02
Authors: Andreas Metzner; Peter Rausch; Christine Lemes; Bruno Reissmann; Alexander Bardyszewski; Roland Tilz; Andreas Rillig; Shibu Mathew; Sebastian Deiss; Masashi Kamioka; Tobias Toennis; Tina Lin; Feifan Ouyang; Karl-Heinz Kuck; Erik Wissner Journal: J Cardiovasc Electrophysiol Date: 2014-01-30
Authors: Erik Wissner; Christian-Hendrik Heeger; Hanno Grahn; Bruno Reissmann; Peter Wohlmuth; Christine Lemes; Peter Rausch; Shibu Mathew; Andreas Rillig; Sebastian Deiss; Tillman Maurer; Tina Lin; Roland Richard Tilz; Feifan Ouyang; Karl-Heinz Kuck; Andreas Metzner Journal: Europace Date: 2015-04-12 Impact factor: 5.214
Authors: Andreas Metzner; Andre Burchard; Peter Wohlmuth; Peter Rausch; Alexander Bardyszewski; Christina Gienapp; Roland Richard Tilz; Andreas Rillig; Shibu Mathew; Sebastian Deiss; Hisaki Makimoto; Feifan Ouyang; Karl-Heinz Kuck; Erik Wissner Journal: Circ Arrhythm Electrophysiol Date: 2013-06-07
Authors: Vivek Y Reddy; Lucie Sediva; Jan Petru; Jan Skoda; Milan Chovanec; Zita Chitovova; Paola Di Stefano; Ethel Rubin; Srinivas Dukkipati; Petr Neuzil Journal: J Cardiovasc Electrophysiol Date: 2015-04-15
Authors: Kivanc Yalin; Amr Abdin; Evgeny Lyan; Noureddin Sawan; Spyridon Liosis; Christian Elsner; Alexander Jobs; Ben Brüggemann; Jelena Koester; Ingo Eitel; Charlotte Eitel; Roland Richard Tilz Journal: Clin Res Cardiol Date: 2018-02-28 Impact factor: 5.460
Authors: Hugo Enrique Coutiño; Carlo de Asmundis; Giacomo Mugnai; Darragh Moran; Valentina De Regibus; Erwin Ströker; Ken Takarada; Diego Ruggiero; Rajin Choudhury; Stefan Beckers; Carla Van Gompel; Jan Poelaert; Saverio Iacopino; Pasquale Filannino; Pedro Brugada; Gian-Battista Chierchia Journal: J Interv Card Electrophysiol Date: 2016-08-25 Impact factor: 1.900
Authors: Thomas Kleemann; Johannes Brachmann; Thorsten Lewalter; Dietrich Andresen; Stephan Willems; Stefan G Spitzer; Ellen Hoffmann; Lars Eckardt; Matthias Hochadel; Jochen Senges; Karl-Heinz Kuck; Karlheinz Seidl; Ralf Zahn Journal: Clin Res Cardiol Date: 2016-05-03 Impact factor: 5.460